Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

85.66
+3.334.04%
Post-market: 85.660.00000.00%19:45 EST
Volume:277.41K
Turnover:22.93M
Market Cap:1.01B
PE:-24.27
High:85.95
Open:81.89
Low:78.17
Close:82.33
52wk High:114.69
52wk Low:18.05
Shares:11.84M
Float Shares:7.16M
Volume Ratio:1.06
T/O Rate:3.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5291
EPS(LYR):-7.8322
ROE:-301.19%
ROA:-47.54%
PB:26.21
PE(LYR):-10.94

Loading ...

Palvella Therapeutics COO Kathleen Goin Disposes of Common Shares

Reuters
·
Yesterday

Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum

TIPRANKS
·
Feb 18

Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 16

Analysts’ Top Healthcare Picks: Cogstate Ltd (COGZF), Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 13

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Feb 10

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Progyny (PGNY)

TIPRANKS
·
Feb 09

Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Feb 03

Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating

TIPRANKS
·
Feb 03

Palvella Therapeutics management to meet virtually with Craig-Hallum

TIPRANKS
·
Feb 02

Palvella Therapeutics to Advance QTORIN Pitavastatin into Phase 2 Trials for Porokeratosis

Reuters
·
Feb 02

Palvella Therapeutics Inc : TD Cowen Raises Target Price to $190 From $133

THOMSON REUTERS
·
Feb 02

Analysts’ Top Healthcare Picks: Danaher (DHR), Palvella Therapeutics (PVLA)

TIPRANKS
·
Jan 31

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Dow Jones
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Jan 29

Palvella Therapeutics (PVLA) Receives a Buy from BTIG

TIPRANKS
·
Jan 21

Palvella Therapeutics Price Target Maintained With a $192.00/Share by BTIG

Dow Jones
·
Jan 17

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)

TIPRANKS
·
Jan 16

Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics

TIPRANKS
·
Jan 14

BUY Rating on Palvella Therapeutics: De-Risked SELVA Phase 3 Design Positions QTORIN Rapamycin for First-in-Class MLM Approval and Compelling Risk–Reward

TIPRANKS
·
Jan 10

BRIEF-Palvella Therapeutics Provides Corporate Update And 2026 Outlook

Reuters
·
Jan 09